S&P Futures
3,927.25 +4.50 (+0.11%) Dow Futures
31,481.00 +41.00 (+0.13%) Nasdaq Futures
11,932.00 -3.50 (-0.03%) Russell 2000 Futures
1,777.50 +4.70 (+0.27%) Crude Oil
110.50 +0.91 (+0.83%) Gold
1,814.40 -1.50 (-0.08%)
Equillium, Inc. (EQ)
Chart Events
Performance Outlook
| Previous Close | 2.4800 |
| Open | 2.4500 |
| Bid | 2.4100 x 900 |
| Ask | 2.7100 x 1800 |
| Day's Range | 2.4400 - 2.7100 |
| 52 Week Range | 2.1200 - 7.7500 |
| Volume | |
| Avg. Volume | 34,467 |
| Market Cap | 77.151M |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3510 |
| Earnings Date | Mar 22, 2022 - Mar 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.50 |
- Business Wire
Equillium to Present at Two Upcoming Investor Conferences
LA JOLLA, Calif., May 17, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will be presenting at the H.C. Wainwright Global Investment Conference and the Jefferies Healthcare Conference.
- Business Wire
Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development Updates
LA JOLLA, Calif., May 12, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs.
- Business Wire
Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association
LA JOLLA, Calif., May 12, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that the European Hematology Association (EHA) has published an abstract highlighting the Phase 3 EQUATOR study in first-line acute graft-versus-host disease (aGVHD).
